Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Status:
Completed
Trial end date:
2020-06-15
Target enrollment:
Participant gender:
Summary
This clinical trial is for men and women with whose lymphoma (non-Hodgkin or Hodgkin) did not
respond to treatment or has returned after responding to previous therapy, and who are in
need of a stem cell transplant.
The purpose of this study is to test the safety and effectiveness of giving the drug
Bendamustine, followed by high dose chemotherapy, within two weeks prior to a stem cell
transplant for lymphoma that has not achieved a complete response to salvage (treatment used
for relapsed disease) chemotherapy.